CAU
VRNA

Caxton Associates (UK)’s Verona Pharma VRNA Stock Holding History

Caxton Associates (UK)’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,716
Closed -$3.38M – 942
2025
Q2 		$3.38M Buy
+35,716
New +$2.64M 0.09% 117

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caxton Associates (UK)'s VRNA Position: Q3 2025 in Review

Caxton Associates (UK) sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 35,716 shares — an estimated $3.38M sold.

Caxton Associates (UK) first reported a position in VRNA in Q2 2025 and held it in 1 quarter. The position peaked at $3.38M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Caxton Associates (UK) reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 35,716 Verona Pharma shares in Q3 2025, an estimated $3.38M.
  • Caxton Associates (UK) first reported a position in Verona Pharma in Q2 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s Verona Pharma position peaked at $3.38M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Caxton Associates (UK)'s 13F filing for Q3 2025, filed 17 Nov 2025.